Abstract 899P
Background
Standard of care (SOC) treatment (ttm) of HNSCC patients (pts) was compromised and had to be adapted during the COVID-19 pandemic due to collapse of the healthcare system. The IMPACCT study evaluated the impact of COVID19 on ttm and outcome in pts diagnosed during the first-wave (Guillen, P. ASCO 2021, P6061). The 3-year follow-up results are presented.
Methods
Retrospective cohort analysis of newly diagnosed HNSCC pts from January to June 2020 treated with curative intent (CT20) at Institut Català d’Oncologia (ICO). A cohort treated during the same period at ICO from 2018 and 2019 was used as a control group (CG). Pts were followed until 3 years after diagnosis. Clinical characteristics were obtained from in-house prospective database. Ttm deviations from SOC per COVID-19 contingency protocol (CCP) in CT20 were collected. Recurrence-free survival (RFS) and overall survival (OS) rates from 6 to 36 months (m) were compared among cohorts by Log-rank test.
Results
A total of 306 pts were included: CT20=99; CG=207. Despite balanced disease characteristics, a lower proportion of pts underwent surgery as primary ttm in CT20 vs CG (47 vs 60%, p=0.04). In conservative treated pts, persistence disease rate was higher in CT20 vs CG (25 vs 10% p=0.03). CT20 had significantly lower RFS and OS rates only at 6 and 12m, when compared to CG (see table). Within CT20 pts, 39% had ttm modifications from SOC: 27% due to CCP (surgery to conservative ttm 13%, reduction of high-dose cisplatin to 2 cycles 10%, altered radiotherapy 2%, no induction/adjuvant ttm 2%) and 12% due to COVID-19 (delay of ttm start 9%, upstaging 3%). 3-year RFS nor OS did not differ in pts with ttm modifications vs unmodified ones (57 vs 43% p=0.2; 67 vs 55% p=0.1, respectively).
Table: 899P
6m | 12m | 18m | 24m | 36m | |
RFS (%) | |||||
CG | 88 (83.5-92,7) | 76.0 (70.2-82.3) | 68.2 (62.0-75.1) | 63.0 (56.5-70.2) | 57.3 (50.7-64.7) |
CT20 | 79.8 (71.9-88.6) | 65.2 (56.0-75.9) | 61.8 (52.5-72.8) | 58.4 (49.0-69.6) | 48.6 (39.1-60.4) |
p=0.082 | p=0.055 | p=0.19 | p=0.29 | p=0.13 | |
OS (%) | |||||
CG | 95.8 (93.0-98.7) | 85,3 (80.5-90.5) | 78.5 (72.9-84.6) | 74.9 (69.0-81.3) | 69.6 (63.4-76.5) |
CT20 | 88.9 (82.6-95.6) | 83.3 (76.0-91.4) | 72.2 (63.5-82.1) | 67.7 (58.7-78.1) | 61.6 (52.3-72.7) |
p= 0.025 | p=0.58 | p=0.23 | p=0.20 | p=0.16 |
Conclusions
The COVID-19 pandemic led to ttm modifications from SOC and had an early detrimental impact on RFS and OS when compared to prior years. Ttm modifications did not seem to explain survival differences. Further analyses are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Brenes Castro: Financial Interests, Personal, Advisory Role: Merck, Bristol Myers Squibb, Takeda; Financial Interests, Personal, Other, Travel/Accommodation: MSD, Merck, Bristol Myers Squibb, Transgene; Financial Interests, Personal and Institutional, Research Grant: GSK. M. Plana Serrahima: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Institutional, Other: Nanobiotix. M. Oliva: Financial Interests, Personal, Invited Speaker: BMS, Merck, MSD; Financial Interests, Personal, Other, Teaching activities: Merck, MSD; Financial Interests, Personal, Advisory Board: Merck, MSD; Financial Interests, Personal, Writing Engagement: MSD; Financial Interests, Personal, Other, IDMC: Transgene; Non-Financial Interests, Institutional, Local PI: AbbVie, ALX Oncology, Ayala Therapeutics, Bayer, Boehringer Ingelheim, Debiopharm, Gilead, ISA Therapeutics BV, Merck, MSD, Roche, Seagen; Non-Financial Interests, Institutional, Funding: GSK; Non-Financial Interests, Personal and Institutional, Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12